16:12 EDT Humacyte drops 17% as FDA needs more time for ATEV review
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUMA:
- Humacyte Announces FDA Communication of Additional Time Required to Complete Review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma
- Hertz Global Holdings call volume above normal and directionally bullish
- HUMA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Humacyte to participate in a conference call with Benchmark
- Humacyte ATEV meets primary endpoints in V007 Phase 3 trial